Koers Cronos Group Inc Toronto S.E.
Aandelen
CA22717L1013
Farmaceutische producten
Omzet 2024 * | 137 mln. 100 mln. 93,82 mln. | Omzet 2025 * | 164 mln. 120 mln. 112 mln. | Marktkapitalisatie | 1,35 mld. 986 mln. 923 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -17 mln. -12,43 mln. -11,63 mln. | Nettowinst (verlies) 2025 * | -10 mln. -7,31 mln. -6,84 mln. | EV/omzet 2024 * | 1,18 x |
Nettoliquiditeiten 2024 * | 1,19 mld. 868 mln. 812 mln. | Nettoliquiditeiten 2025 * | 1,19 mld. 871 mln. 815 mln. | EV/omzet 2025 * | 0,96 x |
K/w-verhouding 2024 * |
-57,5
x | K/w-verhouding 2025 * |
-51,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 52,38% |
Recentste transcriptie over Cronos Group Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 37 | 06-11-15 | |
James Holm
DFI | Director of Finance/CFO | 41 | 14-11-22 |
Arye Weigensberg
CTO | Chief Tech/Sci/R&D Officer | 41 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 48 | 25-06-21 | |
James D. Rudyk
BRD | Director/Board Member | 57 | 01-02-18 |
Jason Adler
BRD | Director/Board Member | 52 | 12-07-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+35,04% | 5,92 mld. | |
-15,13% | 4,51 mld. | |
-9,75% | 3,15 mld. | |
+2,14% | 3,1 mld. | |
-6,82% | 2,42 mld. | |
+47,87% | 1,97 mld. | |
-7,89% | 1,68 mld. | |
+0,09% | 1,65 mld. | |
-12,97% | 1,53 mld. |